Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

OptimizeRx Corp

NASDAQ: OPRX · Trade & Services · 2 alerts · CIK 1448431

Share price
$6.64Close, Nov 16
Market cap
$126M
Shares outstanding
18.91MLatest SEC cover page
Sector
Trade & Services
Industry
Services-Business Services, NECSIC 7389

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All OptimizeRx Corp filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

OptimizeRx Q3 2026 Results: Net Income $1.2M, Up 53.4% YoY

For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.

Key figure
Net income $1.2M · +53.4% YoY
4:08 PM ET 8-K
Financial Results

OptimizeRx Financial Results

OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.

Term
Q3 2026

“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”

Stephen L. Silvestro, OptimizeRx CEO

“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”

Stephen L. Silvestro, OptimizeRx CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.